
When To Lower The Crib Mattress: A Thorough Guide
Wouldn't it be nice if there was an exact age to lower your baby's crib mattress? Like most things in parenting, there is some nuance to this decision. Once your baby's milestones or skill level make the current crib height unsafe, it's time to lower it. To learn more about safe sleep and when to lower the mattress, we interviewed a pediatrician and reviewed safe sleep guidelines from the American Academy of Pediatrics (AAP).
Lower the crib mattress when your baby's skills make their mattress height unsafe.
Keeping your baby safe in their crib is about more than just mattress height. 'Generally, the more basic, the better—babies should sleep on their back, alone on a firm surface with a fitted sheet, and in a location with four walls (like a bassinet, crib or play yard). Nothing else,' says Dr. Christopher Culler, associate chief of pediatrics at Nemours Children's Health in Orlando, Florida. The best crib mattresses are firm, according to the AAP safe sleep guidelines, which help reduce the risk of sudden infant death syndrome (SIDS). Choosing the right crib mattress size can also help ensure your baby doesn't get trapped between the sides of the crib and the mattress.
Though it can be tempting to add crib bumpers, pillows or blankets, these items are not safe for babies. Even once your baby suddenly becomes a toddler when they turn 1, most crib manufacturers advise parents not to place any extra items in the crib while it's in crib mode.
As for lowering the crib, it's imperative to do it at the right time to prevent your baby from falling out of the crib. 'The mattress should always be kept low enough that the baby or toddler cannot climb out,' says Culler. When in doubt, there is no harm in lowering the crib mattress earlier than you think you need to. The higher height setting simply makes it easier on your back when picking baby up or setting them down.
Most cribs have three mattress settings. The highest setting is ideal for newborns, because you don't have to bend down so far to get them in and out of the crib. As they achieve new abilities and surpass milestones, the crib height should be lowered to keep them safe. Make sure you're moving the crib mattress down when your baby shows they can do these things anywhere, not just when they do them in their crib. If they can pull to stand on the side of the couch, they can do it in their crib.
Once a baby can up or get onto their hands and knees, move the crib mattress from the highest to the middle height setting. Typically, this happens between 6 and 9 months, though it can happen sooner, so keep a close eye on your baby's skills.
If your newborn is using a bassinet versus a crib, you may need to switch over to a crib before 6 months. Most bassinet manufacturers recommend parents switch babies to a crib once they are able to roll over. Once in the crib, they can stay at the top mattress setting until they can sit or get onto their hands and knees.
Somewhere around 9 months, many babies begin to pull to stand, and the crib slats often provide an ideal place for them to practice. At this point, move the crib mattress down to the lowest setting so they don't topple out when they pull themselves up.
Eventually, your baby will outgrow their crib. For many little ones, this happens around 18 to 24 months. As soon as they start to try climbing out of their crib, it's best to switch them to a toddler bed, floor bed or big kid bed. Your crib might even convert into a toddler bed with the removal of one side. You don't want them to get injured trying to climb out.
Even if they're not trying to climb out, you may need to move out of the crib around this age. Most crib manufacturers recommend that toddlers move out of the crib once they reach 35 inches tall or when the top rail of the crib is at or below nipple height when they're standing in it.
Once you get the mattress to the lowest setting, it's important to keep it there. Unless specifically approved by your crib's manufacturer, it's not safe to put the crib mattress on the floor. Sometimes parents want to do this to extend how long their baby can stay in their crib, but it often simply isn't safe.
For the best advice on how to lower a crib mattress, follow the directions in your crib's instruction manual. In general, here are the steps you'll take:
At What Age Can Babies Sleep On A Softer Mattress?
Generally, it's recommended that babies sleep on a firm surface until 12 months. After that, your toddler may use a softer mattress. Some crib mattresses have a firm side for babies and a softer side for toddlers.
Is It Safe To Incline A Baby Mattress For Congestion?
No, it is not safe to incline your baby's mattress. Instead, to relieve congestion, try using nasal saline and suction with a bulb syringe or nasal aspirator. You can also try sitting in a warm, steamy bathroom with your baby before bed or running a cool-mist humidifier in their room. This can help clear their nasal passages.
What Is The Best Crib Mattress?
After testing 21 models, we found the best crib mattress to be the Naturepedic Organic Breathable Ultra Baby Crib Mattress (2-Stage) Innerspring. It's durable and has quite a few certifications: EWG Verified, Made Safe and Greenguard Gold. It also has two stages, so you can flip it to the softer side when your toddler is ready.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
36 minutes ago
- Yahoo
Record year for annual Children's Clinic golf outing
ANDERSON — In its 40th year, the annual Kids Classic Pro-Am golf outing attracted a record number of golfers and donations. Organizer Nancy Anderson said Thursday at the Anderson Country Club that a record 220 golfers took part in the annual fundraiser for the Peyton Manning Children's-St. John's Children's Clinic. Advertisement She said a record $131,000 was raised, bringing the total raised to $3 million since the outing began in 1984. Only in 2020, during the COVID-19 pandemic, was there not an annual golf outing to raise funds for the clinic. 'All the funds go 100% to the Children's Clinic,' she said. St. Vincent Ascension Hospital Kids Classic Pro-Am Organizers Brian Hammond and Nancy Anderson discuss the significance of the St. Vincent Ascension Hospital Kids Classic Pro-Am, which celebrated its 40th anniversary Thursday. Anderson said it was the best event ever with a change having golfers take to the golf course in the morning and afternoon. Advertisement Among those in attendance was the Indiana Pacers mascot, Boomer, and two Pacemates, who appeared following the Pacers' win Wednesday night over Oklahoma City in Game 3 of the NBA Finals. They were joined by the mascot for the Indiana Fever of the WNBA. Aaron Loy of Portland was playing in the golf outing for the fourth time, and is the manager for the Children's Clinic. 'It was a no-brainer for me to play,' Loy said. He said he plays golf just once a year. 'It's amazing to see all these people come out and the impact it has throughout the year for all the kids,' Loy said. The clinic serves around 2,000 kids on an annual basis. Advertisement 'We provide everything from annual testing, lab tests. Anything they need we will take care of it,' Loy said. Andrew Brinks has played on a Fredricks Construction team for six years and also only plays once a year. 'Raising money for the Children's Clinic is what brings us out,' he said. 'We're really interested in helping the local foundations in the Madison County area. We're really happy to support this and they do good work here.' The first golf outing took place in 1984 and was hosted by community icon Carl Erskine and community leader Wilbur Roby. In 2009, Erskine passed the torch to Jim and the late Marilyn Ault, who co-chaired alongside former Golf Channel host and Anderson native Brian Hammons. Advertisement There were signs at the entrance honoring Erskine, Roby and Marilyn Ault. Over the years, the event has drawn support from sports and community icons including Peyton Manning, Sandi Patty, Archie Manning, Bill Polian, Larry Bird, and Bobby 'Slick' Leonard. This year the organizers brought in several professional golfers to join local teams. Hammond said the professional golfers were competing for a $12,000 prize.


Associated Press
2 hours ago
- Associated Press
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 15, 2025-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the Company is taking to strengthen the safety profile in non-ambulatory patients. These steps follow a second reported case of acute liver failure (ALF) resulting in death. The cases of ALF to date have both occurred in non-ambulatory individuals with Duchenne. Sarepta extends its deepest sympathies to the affected families and care teams. Key Safety Initiatives Evaluating and Enhancing Immunosuppressive Regimen: As part of a comprehensive review of safety data, Sarepta is taking proactive steps to mitigate the risk of acute liver failure in non-ambulatory patients. Sarepta is working to immediately convene an independent group of leading experts in Duchenne and liver health to consider an enhanced immunosuppression regimen for ELEVIDYS. This panel will evaluate data and assess our proposed regimen, which includes sirolimus and is supported by preclinical data demonstrating the effectiveness of additional immunosuppression in moderating liver enzyme elevations, a key factor in mitigating potential safety events. Sarepta will share the panel's recommendations with the U.S. Food & Drug Administration (FDA), and implementation of any new regimen will be subject to FDA guidance and allowance. Suspending Shipments of ELEVIDYS for Non-Ambulatory Patients: Sarepta is temporarily suspending shipments of ELEVIDYS for non-ambulatory patients while an enhanced immunosuppressive regimen is evaluated, discussed with regulatory bodies, and put in place. For ambulatory patients, no treatment changes are being proposed and the current practice of administering corticosteroids before and after ELEVIDYS infusion, along with post-treatment monitoring, remains the same. ENVISION Study Paused: Sarepta has voluntarily paused dosing in the ENVISION clinical study (also known as Study SRP-9001-303). FDA concurs with this action. The pause will allow for the evaluation of a protocol amendment to incorporate an enhanced immunosuppressive regimen for the non-ambulatory patient cohort and incorporate any additional feedback from the FDA. Regulatory alignment is needed before screening and dosing in ENVISION may resume. ENVISION is a global, randomized, double-blind, placebo-controlled trial evaluating ELEVIDYS in older ambulatory and non-ambulatory individuals living with Duchenne muscular dystrophy. In the U.S., it serves as the confirmatory trial required under the FDA's accelerated approval pathway for non-ambulatory patients. 'Our paramount priority is the safety and well-being of the patients we serve. We are taking immediate, decisive steps to better understand and mitigate the risk of acute liver failure, including enhancing the immunosuppressive regimen, for those with Duchenne who are non-ambulatory,' said Louise Rodino-Klapac, Ph.D., chief scientific officer and head of research & development, Sarepta. 'We are deeply saddened by the loss of a second patient and extend our heartfelt condolences to the patient's family and his care team during this incredibly difficult time. Duchenne muscular dystrophy is a devastating disease that profoundly affects lives and often cuts them far too short. With more than 900 individuals treated to-date, we know how much hope families place in new treatment options like ELEVIDYS – and we are committed to honoring that hope by acting swiftly, guided by scientific rigor and the insights of leading experts, to strengthen safety for all future patients.' Commitment to Long-Term Safety and Understanding Sarepta remains committed to a thorough approach and the highest standards of patient safety and scientific rigor. The event has been reported to FDA and global health authorities and will inform ongoing discussions around a potential label update to reflect the risk of severe ALF and additional immune management strategies for non-ambulatory patients. While elevated liver enzymes are a known class effect of all AAV-based gene therapies, the exact mechanism behind AAV-related liver toxicity remains unclear. Current evidence suggests it is likely driven by an adaptive immune response. The Company will provide additional updates as appropriate. Investor Conference Call Details Sarepta will be hosting a conference call and webcast to discuss this update and provide an update on the Company's business on Monday, June 16, 2025, at 8:00 am Eastern time. The event will be webcast live under the investor relations section of Sarepta's website at: and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Acute Serious Liver Injury: Immune-mediated Myositis: Myocarditis: Preexisting Immunity against AAVrh74: Adverse Reactions: Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website We encourage investors and potential investors to consult our website regularly for important information about us. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials, ELEVIDYS, the potential benefits of an enhanced immunosuppression regimen in dosing in non-ambulatory patients, and expected plans and milestones, including providing additional updates as appropriate and engaging with regulators on an enhanced immunosuppressive regimen for dosing in non-ambulatory patients. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials are positive, these data may not be sufficient to support approval by the FDA or other global regulatory authorities; success in clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or with advisory committee recommendations, or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; we may not be able to comply with all FDA requests in a timely manner or at all; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to source version on CONTACT: Investor Contact: Ian Estepan 617-274-4052 [email protected] Contacts: Tracy Sorrentino 617-301-8566 [email protected] Hoeger 617-710-3898 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: INFECTIOUS DISEASES HEALTH GENETICS PHARMACEUTICAL CLINICAL TRIALS SOURCE: Sarepta Therapeutics, Inc. Copyright Business Wire 2025. PUB: 06/15/2025 01:00 AM/DISC: 06/15/2025 01:01 AM

Associated Press
2 hours ago
- Associated Press
NovoSculpt Named Best Body Contouring Clinic in the Tri-State Area for 2025
NovoSculpt has been honored as the Best Body Contouring Clinic in the Tri-State Area for 2025, solidifying its place as a leader in aesthetic care and body sculpting services. Greenwich, CT, USA, June 15, 2025 -- NovoSculpt Celebrates Prestigious Recognition in Body Contouring Excellence NovoSculpt proudly announces its recognition as the Best Body Contouring Clinic in the Tri-State Area for 2025, a prestigious title that highlights the clinic's leadership in the rapidly growing field of body sculpting. The award emphasizes NovoSculpt's unwavering commitment to providing safe, effective, and customized solutions for those seeking transformative aesthetic results. The recognition celebrates the clinic's dedication to patient care, innovative treatments, and personalized experiences, solidifying its position as the premier destination for body contouring in the region. NovoSculpt's approach to aesthetic medicine continues to disrupt traditional methods by focusing on minimally invasive treatments that provide lasting and natural results. A Cutting-Edge Approach to Minimally Invasive Fat Removal At the heart of NovoSculpt's success is its groundbreaking minimally invasive fat removal procedure, which allows patients to remove up to 11 pounds of localized fat in a single session. This innovative technique eliminates the need for scalpels, stitches, or general anesthesia, providing a safe and efficient solution for body sculpting. The procedure ensures a quick recovery time, with many patients resuming their daily activities in as little as 24 hours. NovoSculpt's approach has proven to be a highly effective and patient-friendly alternative to traditional body contouring surgeries, enabling clients to achieve their desired body shape with minimal discomfort and downtime. This cutting-edge method continues to set NovoSculpt apart from other clinics in the Tri-State Area and positions the clinic as a trailblazer in the aesthetic industry. Led by Expertise: Roberto Magana and a Skilled Team NovoSculpt's success is driven by the vision and leadership of its founder and CEO, Roberto Magana, MBA. With over 15 years of experience in business strategy and leadership, Roberto's guidance has been pivotal in shaping the clinic's operations and ensuring the highest standards of care. Under his leadership, NovoSculpt has assembled a highly skilled team of medical professionals, including elite plastic surgeons and experienced staff, all of whom are dedicated to delivering exceptional results for every patient. Roberto's commitment to operational excellence and patient satisfaction has been integral to the clinic's rapid growth and its recognition as the top body contouring clinic in the region. The clinic's collaboration with top-tier medical personnel ensures that each patient receives comprehensive care, with personalized treatment plans designed to meet their unique goals. Building Trust with Transparent and Safe Practices NovoSculpt's reputation is built on trust, transparency, and an unwavering focus on safety. The clinic operates within a QuadA-certified surgical suite, ensuring that every procedure is conducted in a safe and controlled environment. This certification is a reflection of the clinic's commitment to adhering to the highest medical and safety standards, providing clients with peace of mind throughout their body sculpting journey. By prioritizing patient safety and comfort, NovoSculpt has earned a loyal clientele who often return to enhance additional areas or recommend the clinic to others—confident in its ability to deliver authentic, natural-looking results in a single session. The clinic's client-first approach has fostered strong, lasting relationships with patients, many of whom experience meaningful boosts in confidence and overall well-being. Patient Satisfaction and Proven Results NovoSculpt's minimally invasive approach consistently results in high patient satisfaction, with many clients experiencing impressive, natural-looking results after just one session. The clinic's innovative fat removal procedure has become the preferred choice for those seeking to reshape their bodies without undergoing more invasive surgical procedures. In addition to fat removal, NovoSculpt offers a range of aesthetic treatments, including skin tightening with NovoTight™ and fat transfer for sculpted curves. These services are customized to each patient's specific needs, ensuring that every treatment plan aligns with their personal aesthetic vision. This personalized approach has contributed to NovoSculpt's reputation for excellence and its status as the top body contouring clinic in the Tri-State Area. A Vision of Innovation and Care NovoSculpt's success story is one of innovation, care, and patient-centric solutions. Founded by Roberto Magana, the clinic was created with the goal of offering a minimally invasive, highly effective approach to body contouring. Roberto's vision has led to the development of a clinic that fills the gaps in the market for minimally invasive, customized body sculpting treatments that deliver lasting results. As the clinic continues to innovate and grow, NovoSculpt's commitment to patient satisfaction and exceptional care remains at the forefront. The clinic's ability to adapt to changing industry trends while maintaining its focus on personalized, safe, and effective treatments has allowed it to remain a leader in the body contouring field. Celebrating Success: The 2025 Recognition NovoSculpt's recognition as the Best Body Contouring Clinic in the Tri-State Area for 2025 is a monumental achievement that celebrates the clinic's leadership, innovation, and dedication to its patients. This award reaffirms NovoSculpt's position as a disruptor in the body contouring industry, offering cutting-edge treatments that prioritize both safety and transformative results. As the clinic looks toward the future, it remains committed to setting the standard for excellence in aesthetic medicine. With a growing reputation for delivering remarkable body sculpting results, NovoSculpt continues to reshape the way individuals approach body contouring and aesthetic care. About NovoSculpt NovoSculpt is a leading body contouring clinic based in Greenwich, Connecticut, specializing in minimally invasive targeted fat removal, precision skin tightening, and aesthetic fat transfers—all performed to enhance body contours with immediate, visible results after a single session. No repeat treatments are necessary. Serving clients across the Tri-State Area and beyond, the clinic offers personalized body sculpting solutions tailored to each patient's goals. Founded by Roberto Magana, MBA, NovoSculpt combines cutting-edge technology, a skilled medical team, and a patient-centered approach to deliver safe, effective, and lasting results—without the need for traditional surgery. Media Contact Roberto Magana, MBA Founder & CEO, NovoSculpt Website: Email: [email protected] Instagram: @novosculptus Facebook: @NovoSculpt TikTok: @novosculptus LinkedIn: NovoSculpt Contact Info: Name: Roberto Magana Email: Send Email Organization: NovoSculpt Website: Release ID: 89162338 If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.